Avalo Therapeutics Q2 2026 net loss $36.4M; plans Phase 3 for abdakibart in HS in H1 2027

Avalo Therapeutics, Inc.

2026-Q2 EPS reported -$1.75

Net loss of $36.4M for Q2 2026, up from $20.8M in Q2 2025; diluted EPS of ($0.83) vs ($1.92).
Cash, equivalents and investments of $472.2M as of June 30, 2026, expected to fund operations into 2029.
R&D expenses $23.4M, including $10.0M development milestone for abdakibart; G&A $8.1M.
Plans to initiate registrational Phase 3 program for abdakibart in hidradenitis suppurativa in H1 2027.
Expanded pipeline with AVTX-010 (anti-IL-1β antibody); IND submission planned for H1 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.